Cited by

• Current pharmacological treatments for COVID-19: What's next?

  Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A. Scavone C, et al. Br J Pharmacol. 2020 Nov;177(21):4813-4824. doi: 10.1111/bph.15072. Epub 2020 May 15. Br J Pharmacol. 2020. PMID: 32329520 Free PMC article. Review.
• In-line treatments and clinical initiatives to fight against COVID-19 outbreak.

  Agrawal M, Saraf S, Saraf S, Murty US, Kurundkar SB, Roy D, Joshi P, Sable D, Choudhary YK, Kesharwani P, Alexander A. Agrawal M, et al. Respir Med. 2022 Jan;191:106192. doi: 10.1016/j.rmed.2020.106192. Epub 2020 Oct 17. Respir Med. 2022. PMID: 33199136 Free PMC article. Review.
• Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control.

  Gould EA, Coutard B, Malet H, Morin B, Jamal S, Weaver S, Gorbalenya A, Moureau G, Baronti C, Delogu I, Forrester N, Khasnatinov M, Gritsun T, de Lamballerie X, Canard B. Gould EA, et al. Antiviral Res. 2010 Aug;87(2):111-24. doi: 10.1016/j.antiviral.2009.07.007. Epub 2009 Jul 16. Antiviral Res. 2010. PMID: 19616028 Free PMC article. Review.
• Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.

  Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Colafrancesco S, et al. Front Immunol. 2020 Jun 23;11:1439. doi: 10.3389/fimmu.2020.01439. eCollection 2020. Front Immunol. 2020. PMID: 32655577 Free PMC article. Review.
• Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?

  Machiels JD, Bleeker-Rovers CP, Ter Heine R, Rahamat-Langendoen J, de Mast Q, Ten Oever J, Bousema T, van Crevel R, Wertheim HF. Machiels JD, et al. Int J Antimicrob Agents. 2020 Jul;56(1):106056. doi: 10.1016/j.ijantimicag.2020.106056. Epub 2020 Jul 13. Int J Antimicrob Agents. 2020. PMID: 32674929 Free PMC article. Review.